Applied BioCode Stock

Applied BioCode Shares Outstanding

The The number of shares of Applied BioCode (6598.TW) as of Sep 10, 2026 is 90.62 M. In the previous year, The number of shares was 90.62 M — a change of 0.00% (lower).

Shares Outstanding

90.62 M

YoY

0.00%

Last updated:

In 2026, Applied BioCode had 90.62 M outstanding stocks, a 0.00% change from the 90.62 M stocks in the previous year.

The Applied BioCode Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2019
90.62 M TWD
Jan 1, 2020
90.62 M TWD
Jan 1, 2021
90.62 M TWD
Jan 1, 2022
90.62 M TWD
Jan 1, 2023
90.62 M TWD
Jan 1, 2024
90.62 M TWD
Jan 1, 2025
90.62 M TWD
Jan 1, 2026 (e)
102.65 TWD
The Applied BioCode Shares Outstanding history
YEARShares OutstandingYoY
est102.65-100.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M0.00%
90.62 M
Access this data via the Eulerpool API

Applied BioCode Number of shares

Applied BioCode shares outstanding

The number of shares of Applied BioCode was 102.65 M in 2025. This indicates how many shares Applied BioCode is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
71.16 M Stocks
Jan 1, 2020
81.59 M Stocks
Jan 1, 2021
81.73 M Stocks
Jan 1, 2022
81.69 M Stocks
Jan 1, 2023
81.77 M Stocks
Jan 1, 2024
102.79 M Stocks
Jan 1, 2025
102.65 M Stocks
Jan 1, 2026 (e)
102.65 M Stocks

Applied BioCode Stock analysis

What does Applied BioCode do? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Applied BioCode's Shares Outstanding

Applied BioCode's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Applied BioCode’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Applied BioCode’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Applied BioCode’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Applied BioCode stock

The number of shares of Applied BioCode is 90.62 M in 2026.

The number of shares of Applied BioCode changed from 90.62 M to 90.62 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Applied BioCode since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

Other — Applied BioCode

All Key Metrics — Applied BioCode